Skip to main content

Security report for angelinipharma.gr

Angelini Pharma Hellas Μονοπρόσωπη Α.Β.Ε.Ε. · Healthcare · Greece

Low risk. 2 critical or high findings in GDPR outside view and SSL/TLS.

Security score

80/100

Risk levelLow

0–100, higher is better. How it is calculated

Angelini Pharma Hellas is a specialized pharmaceutical company focused on healthcare sectors including the Central Nervous System, mental health, pain management, rare diseases, and consumer health products. The company holds a strong market position as a leader in healthcare within Greece and is part of the larger Angelini S.p.a. group. Their website provides comprehensive corporate information, product details, and news updates, targeting healthcare professionals and consumers interested in pharmaceutical products. Technically, the website uses modern JavaScript libraries and analytics tools such as Piwik PRO, ensuring moderate performance and good mobile optimization. Security posture is solid with HTTPS enforced and cookie consent mechanisms in place, though some security headers could be improved. Overall, the site is professional, trustworthy, and compliant with GDPR regulations.

Scanned

NIS2 and GDPR posture

GDPR outside view
68/ 100 · Medium
Checks completed
7of 7

NIS2 Art. 21(2)

  1. (a) Risk analysis and security policies: Not visible from outside
  2. (b) Incident handling: One indicator
  3. (c) Business continuity, backups and crisis management: Not visible from outside
  4. (d) Supply chain security: Not visible from outside
  5. (e) Secure acquisition, development and maintenance, including vulnerability handling: Partly checked
  6. (f) Assessing the effectiveness of security measures: Not visible from outside
  7. (g) Cyber hygiene and security training: Not visible from outside
  8. (h) Cryptography and encryption: Partly checked
  9. (i) HR security, access control and asset management: One indicator
  10. (j) Multi-factor authentication and secured communications: Not visible from outside

This scan rated NIS2 with an earlier keyword method that is no longer shown; rescan for the per-article view. Risk management, continuity, supply chain, training, MFA, management oversight (Art. 20) and incident reporting (Art. 23) need internal evidence, and Guard cannot tell whether NIS2 applies to this organisation.

GDPR is indicative only, based on publicly visible signals: Articles 7, 12, 13 and 32 of Regulation (EU) 2016/679 and Article 5(3) of the ePrivacy Directive. Not a certification or legal assessment.

Priority findings

2 findings rated critical or high. Fix these first.

  1. GDPR outside view

    These are the privacy signals visitors and data protection authorities look for under GDPR.

    • High

      No Cookie Consent Banner found

      GDPR requires explicit consent for non-essential cookies

      What to do: Implement a cookie consent banner that appears on first visit

  2. SSL/TLS

    TLS encrypts the connection and proves the site is really yours. Weak or expiring certificates trigger browser warnings and put traffic at risk.

    • High

      Weak Protocols Supported

      Server supports weak protocols: TLSv1.1

      What to do: Disable TLS 1.0, TLS 1.1, and all SSL versions

      • CWE-327
      • OWASP A04:2025
      • ASVS V12.1.1

Need hands-on remediation? Email guard@offseq.com

Keep watching angelinipharma.gr

This scan found 17 issues across 6 checks. Monitoring re-runs those checks daily, emails you when something material changes and records each fix, so you can show progress.

Daily monitoring

Recommended

€25per month

  • TLS certificates and expiry
  • DNS records
  • SPF, DKIM and DMARC
  • Security headers
  • GDPR and NIS2 posture
  • Exposed services
  • Third-party trackers
  • Security score drift

Email alerts on material changes and an exportable JSON history of every change.

Billed monthly to your card. Cancel anytime. The full timeline opens with your unlock code.

Full report

€39.90one-time

  • The complete analysis as a PDF you can cite
  • Email delivery with an unlock code
  • Lifetime access to this report

Prices incl. 21% VAT. Secure checkout by Mollie; sold by SEQ SIA, Latvia.

Results by check

Each check with its score, findings and the evidence it collected.

How this score is calculated

The security score runs 0–100, higher is better. It is the plain average of the security checks that completed in this scan, each counted equally. A check that could not run is left out: it counts neither as a pass nor as a fail.

Counted in this score

SSL/TLS
82
Security headers
90
Email security
60
DNS health
80
Network security
100
GDPR outside view
68
Average
80

Not counted

  • NIS2 outside view: Re-weights evidence from the TLS, email, DNS, network and hygiene checks, so counting it would count that evidence twice. Shown on its own.
  • OffSeq Observations: An AI reading of the site, useful context but not reproducible evidence. Shown on its own.

Findings that cap the score at 49

Each of these is serious on its own, so while any is present the site cannot rate better than high risk, however good the other checks are.

  • The certificate is not trusted by browsers
  • The website is not served over HTTPS
  • A database, remote desktop, file-sharing or Telnet service is reachable from the internet
  • The page loads a script from a compromised source
  • The domain registration has expired
  • SPF authorises every server to send mail as the domain

Partial scans

When the site blocks Guard or most checks cannot run, the score covers only the checks that ran (usually DNS and email), is capped at 75 and is shown as partial, without a risk level.

Risk levels

  • Critical0–25
  • High26–49
  • Medium50–75
  • Low76–100

Technical appendix

Business context, site observations and technical notes gathered during the scan, and the standards behind each reference.

Business context

Business profile

Angelini Pharma operates in the healthcare sector with a business model centered on pharmaceutical R&D, manufacturing, and distribution. Their competitive advantage lies in their specialization in CNS and mental health, supported by a broad portfolio of branded products. The company maintains a network of subsidiaries across Europe and the USA, indicating a strong international presence. Their marketing and analytics infrastructure supports moderate user tracking with privacy compliance. The company demonstrates growth potential through partnerships and exclusive licensing agreements highlighted in their news section. The website reflects a mature digital presence with clear branding and consistent messaging.

Security posture

The website demonstrates a good security maturity level with HTTPS enabled and cookie consent implemented. However, explicit security headers such as Content-Security-Policy, X-Frame-Options, and X-Content-Type-Options are not visibly configured, which could enhance protection against common web attacks. No exposed sensitive data or vulnerable libraries were detected in the HTML content. The absence of a published security policy or incident response contact limits transparency in security incident handling. Overall, the security posture is adequate for a corporate pharmaceutical website but could benefit from additional hardening and documentation.

Recommendations

  1. Implement and enforce security headers including Content-Security-Policy, X-Frame-Options, and X-Content-Type-Options to mitigate common web vulnerabilities.
  2. Publish a dedicated security policy and provide clear incident response contact channels to improve transparency and trust.
  3. Regularly audit and update third-party scripts and libraries to avoid potential vulnerabilities.
  4. Enhance accessibility features to improve compliance and user experience for all visitors.
  5. Continue monitoring and optimizing website performance and mobile responsiveness to maintain high user engagement.

Contact details published on the site

Addresses
Legal name
Angelini Pharma Hellas Μονοπρόσωπη Α.Β.Ε.Ε.
Site observations

Automated reading of the public site. Ratings are indicative.

Business

Company
Angelini Pharma Hellas Μονοπρόσωπη Α.Β.Ε.Ε.
Description
Η Angelini Pharma είναι ηγέτης στην υγειονομική περίθαλψη, με ιδιαίτερη δύναμη και εξειδίκευση στους τομείς του Κεντρικού Νευρικού Συστήματος (ΚΝΣ) και της Ψυχικής Υγείας, συμπεριλαμβανομένου του Πόνου και των Σπάνιων Ασθενειών. Η εταιρεία είναι επίσης ένας κορυφαίος παράγοντας στον τομέα της Υγείας των Καταναλωτών, με εξαιρετικά επιτυχημένα επώνυμα προϊόντα ΜΗ.ΣΥ.ΦΑ. παγκοσμίως.
Key services
Pharmaceutical research and development, Manufacturing, Product distribution, Consumer health products
Content quality
good
Branding
consistent

Technology

Stack
jQuery 3.7.1, jQuery Validation Plugin, Slick Carousel, Magnific Popup, Piwik PRO Analytics, Flip.js
Performance
moderate
Mobile
good
Accessibility
basic
SEO
good

Security

Observed score
85/100
Good practices seen
  • HTTPS enforced
  • Cookie consent mechanism implemented
  • No exposed sensitive data in HTML

Analytics and tracking

Services
Piwik PRO
Tracking level
moderate
Privacy practices
good

Advertising

Tracking pixels
Piwik PRO
Marketing tools
Piwik PRO
Transparency
basic

Site quality

Design
good
User experience
good
Content relevance
good
Navigation
good
Professionalism
good
Trustworthiness
high

Key observations

  1. Website is professionally designed and well-structured.
  2. Content is primarily in Greek with some English elements.
  3. Strong focus on healthcare and pharmaceutical industry.
  4. Comprehensive corporate and product information available.
  5. Cookie consent and privacy policies are implemented.
  6. No signs of malicious or suspicious activity detected.
  7. Multiple country-specific subsidiary domains linked.
  8. Social media presence on LinkedIn and YouTube.
  9. Use of modern JavaScript libraries and analytics tools.
Technical notes

Notes

The website uses a modern JavaScript stack including jQuery 3.7.1, Slick Carousel, Magnific Popup, and Flip.js for UI components and interactions. Analytics are handled via Piwik PRO, indicating a preference for privacy-focused tracking. The site loads fonts from a dedicated Angelini Industries domain and uses Google Cloud Storage for media assets. The CMS is not explicitly identified, suggesting a custom or proprietary solution. Performance is moderate with asynchronous loading of scripts and lazy loading of images. The site is mobile optimized with responsive design elements. SEO is supported by proper meta tags and Open Graph data. Technical risks are minimal but could be reduced by adding missing security headers and improving accessibility compliance.
Standards and sources

Reference chips under each finding point to the standard, regulation or specification the finding relates to. They are taken from the official datasets below and mapped conservatively: a finding with no defensible link shows none. NIS2 and GDPR references mark where a finding is relevant evidence, not a compliance verdict. Implementing Regulation (EU) 2024/2690 binds digital infrastructure and digital service providers; for other entities it is the most detailed public reading of the Article 21 measures. WCAG, EN 301 549, European Accessibility Act and Web Accessibility Directive references name the requirement an automated accessibility rule relates to; they are not a conformance verdict.

Retrieved 2026-10-25

Reviews of this site

Share your experience with angelinipharma.gr. Every review is verified by email and published after moderation.

Overall rating
Select a rating
4000 characters remaining

We’ll email you to confirm your review and keep your details private.

Community rating

No published reviews yet. Be the first to review angelinipharma.gr.

Feedback on this report

Rate this report, add an optional comment, and tell us if you want a security specialist to follow up.

Overall report quality
Select a rating
2000 characters remaining

We only use your feedback to improve Guard reports. Contact details are never shared.